GE Healthcare has released immunogenicity software for its Biacore T100 protein interaction analysis system, to support screening, confirmation and characterisation of anti-drug antibodies.
Biacore T100 immunogenicity software addresses the problem of drug interference by enabling measurement of anti-drug antibodies in the presence of excess amounts of drugs.
The package also includes guidelines and recommendations for development of immunogenicity assays.
GE said that the screening of anti-drug antibodies with Biacore instruments has the advantage of detecting early immune responses, which are characterised by antibodies with low affinity.
Such immune responses are important in efficacy and safety studies and may easily be missed by alternative technologies such as end-point assays.
Tools provided by Biacore T100 immunogenicity software also allow for easy confirmation of positive samples and elimination of false positives through drug depletion.
Comprehensive characterisation of immune response by, for example, determination of antibody isotype and anti-drug antibody binding stability can be achieved using dedicated software tools included in the immunogenicity package.
Biacore T100 is used throughout the drug discovery and development process in labs ranging from major pharmaceutical companies to academic research institutes.
